Our team is experienced in small molecule, oral antiviral drug development and passionate about advancing both broad spectrum and direct-acting antivirals for pandemic preparedness. We have driven successful antiviral discovery, development, and clinical trials resulting in FDA approval of 10 antivirals.
Vikram Sheel Kumar, MD
Co-Founder, President, and CEO
Barbara Powers, MSN, PhD
Vice President, Clinical Operations
Nadim Shohdy, PhD
Vice President, Corporate Development
Daniel Geffken, MBA
Chief Financial Officer (Interim)
Maryline Kienle, PhD
Manager, Project & Research Operations
© Clear Creek Bio, 2021 | Privacy Policy | Terms | Design by Ape to Zebra